Apple Inc. founder and chief executive Steve Jobs confronted widespread speculation about his apparent weight loss in a statement issued today that attributed his gaunt appearance to an easily treated hormone imbalance.
The announcement follows a flurry of speculation in 2008 about the 53-year-old CEO's weight loss, including rumors of a worsening pancreatic condition -- rumors Jobs said are unfounded.
Jobs' assertion is buoyed by the fact that the pancreatic condition he survived -- called a neuroendocrine tumor, or NET -- is much less deadly than the more common form of pancreatic cancer that took the lives of "Last Lecture" professor Randy Pausch and New York Times reporter Dith Pran, and which actor Patrick Swayze now faces.
Only about 2,000 to 3,000 neuroendocrine tumor cases are diagnosed in the United States each year, and up to half of those with malignant forms of these tumors are still alive after five years, according to statistics from the National Cancer Institute. When those with nonmalignant forms of these tumors are included, the survival rate is even higher.
Conversely, doctors estimate that about 30,000 people were diagnosed with the deadlier form of pancreatic cancer this year, which has a five-year survival rate of about 5 percent.
"My decision to have [Apple marketing chief] Phil Schiller deliver the Macworld keynote set off another flurry of rumors about my health, with some even publishing stories of me on my deathbed," Jobs noted in his statement. "Fortunately, after further testing, my doctors think they have found the cause -- a hormone imbalance that has been 'robbing' me of the proteins my body needs to be healthy."
Jobs further noted in his letter that the remedy for the problem is "relatively simple and straightforward," and that he has already begun treatment to correct the condition.
An e-mailed message to an Apple spokesperson for further comment was not immediately returned. Following Jobs' announcement, Apple Inc. released a statement indicating that Jobs will continue to hold the CEO post for the company.
Pancreatic cancer experts said an effective lockdown on Jobs' medical particulars since he first announced he had a pancreatic tumor in 2004 makes it difficult to determine for certain the exact nature of his condition.
"He's done a very good job of keeping this private," said Dr. Harold Frucht, associate professor of clinical medicine at Columbia University.
But he said that judging from the information available, it is unlikely that Jobs required a Whipple procedure -- an operation that removes a large portion of the pancreas and can lead to profound hormonal imbalances.
Instead, he said, he believes the surgeon who operated on Jobs probably performed what is called an enucleation -- a procedure in which a doctor in essence scoops a tumor out of the organ, leaving most of the pancreas intact.
"A lot of surgeons would have done a Whipple procedure, but for neuroendocrine tumors this is not generally necessary," Frucht said. "Good surgeons who have dealt with a lot of these tumors would conduct the surgery without taking out the pancreas."